Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, male (% ages 15-24) in Ghana was reported at 0.3 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Ghana - Prevalence of HIV, male (% ages 15-24) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.
Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, South Africa, and Lesotho. In 2024, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids, and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased. However, despite being available worldwide, not all adults have access to antiretroviral drugs. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.
The following slide sets are available to download for presentational use:
New HIV diagnoses, AIDS and deaths are collected from HIV outpatient clinics, laboratories and other healthcare settings. Data relating to people living with HIV is collected from HIV outpatient clinics. Data relates to England, Wales, Northern Ireland and Scotland, unless stated.
HIV testing, pre-exposure prophylaxis, and post-exposure prophylaxis data relates to activity at sexual health services in England only.
View the pre-release access lists for these statistics.
Previous reports, data tables and slide sets are also available for:
Our statistical practice is regulated by the Office for Statistics Regulation (OSR). The OSR sets the standards of trustworthiness, quality and value in the https://code.statisticsauthority.gov.uk/" class="govuk-link">Code of Practice for Statistics that all producers of Official Statistics should adhere to.
Additional information on HIV surveillance can be found in the HIV Action Plan for England monitoring and evaluation framework reports. Other HIV in the UK reports published by Public Health England (PHE) are available online.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Namibia was reported at 11 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Namibia - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Trinidad and Tobago was reported at 1 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Trinidad and Tobago - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.
As of 2023, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.7 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.4 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by Lesotho and South Africa. However, South Africa had the highest total number of new HIV infections in 2023, with around 150,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the fourth leading cause of death in Africa, accounting for around 5.6 percent of all deaths. In 2023, South Africa and Nigeria were the countries with the highest number of AIDS-related deaths worldwide with 50,000 and 45,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years and now up to 95 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 77 percent of people who are HIV positive in South Africa receiving ART, and only 31 percent in the Congo.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in France was reported at 0.3 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. France - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Hungary was reported at 0.1 % in 2018, according to the World Bank collection of development indicators, compiled from officially recognized sources. Hungary - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Peru was reported at 0.4 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Peru - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Romania was reported at 0.1 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Romania - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 45.66(USD Billion) |
MARKET SIZE 2024 | 46.91(USD Billion) |
MARKET SIZE 2032 | 58.2(USD Billion) |
SEGMENTS COVERED | Treatment Options ,Disease Stage ,Patient Population ,Mode of Transmission ,Comorbidities ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Growing prevalence of HIV Advancements in HIV treatment Government initiatives Increasing awareness |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Shionogi & Co. ,GlaxoSmithKline ,Eisai Co. ,Merck & Co. ,BristolMyers Squibb ,Boehringer Ingelheim ,Roche ,Pfizer ,Gilead Sciences ,Johnson & Johnson ,Novartis ,ViiV Healthcare ,AbbVie ,TAKEDA ,Astellas Pharma |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Gene therapyAdvancements in PrEP and PEP Increased focus on early diagnosis Expanded access to antiretroviral therapy Pointofcare diagnostics |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.73% (2025 - 2032) |
Download https://khub.net/documents/135939561/1051496671/Sexually+transmitted+infections+in+England%2C+2024.odp/556ce163-d5a1-5dbe-ecbf-22ea19b38fba" class="govuk-link">England STI slide set 2024 for presentational use.
Download https://khub.net/documents/135939561/1051496671/Sexually+transmitted+infections+in+England+2024.pdf/389966d2-91b0-6bde-86d5-c8f218c443e5" class="govuk-link">STI and NCSP infographic 2024 for presentational use.
The UK Health Security Agency (UKHSA) collects data on all sexually transmitted infection (STI) diagnoses made at sexual health services in England. This page includes information on trends in STI diagnoses, as well as the numbers and rates of diagnoses by demographic characteristics and UKHSA public health region.
View the pre-release access lists for these statistics.
Previous reports, data tables, slide sets, infographics, and pre-release access lists are available online:
The STI quarterly surveillance reports of provisional data for diagnoses of syphilis, gonorrhoea and ceftriaxone-resistant gonorrhoea in England are also available online.
Our statistical practice is regulated by the Office for Statistics Regulation (OSR). The OSR sets the standards of trustworthiness, quality and value in the https://code.statisticsauthority.gov.uk/" class="govuk-link">Code of Practice for Statistics that all producers of Official Statistics should adhere to.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 2.91(USD Billion) |
MARKET SIZE 2024 | 3.02(USD Billion) |
MARKET SIZE 2032 | 4.1(USD Billion) |
SEGMENTS COVERED | Test Type, Sample Type, End User, Technology, Distribution Channel, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Increasing prevalence of HIV infections, Advances in diagnostic technologies, Government initiatives and funding, Growing awareness and education programs, Rise in point-of-care testing |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Roche, Mylan, Beckman Coulter, Cepheid, Becton Dickinson, Quidel, PerkinElmer, Johnson and Johnson, Grifols, Hologic, Abbott, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, BioRad Laboratories |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Point-of-care testing innovations, Increased funding for HIV programs, Growing prevalence of HIV/AIDS, Enhanced data analytics for diagnosis, Rise in telemedicine for diagnostics |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.88% (2025 - 2032) |
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Greece was reported at 0.2 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Greece - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
HIV/AIDS funding by the NIH stood at around *** billion U.S. dollars in fiscal year 2023. This graph shows the total HIV/AIDS funding by the National Institutes for Health (NIH) from FY 2013 to FY 2023 and estimates for FY 2024 and FY 2025.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 39.58(USD Billion) |
MARKET SIZE 2024 | 41.35(USD Billion) |
MARKET SIZE 2032 | 58.8(USD Billion) |
SEGMENTS COVERED | Drug Class ,Route of Administration ,Combination Regimens ,Patient Population ,Generic vs. Branded ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Increase in global HIVAIDS burden Development of advanced and innovative antiretroviral therapies Growing demand for affordable and accessible treatment options Emergence of generic and biosimilar drugs Stringent regulatory policies and reimbursement challenges |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | - Gilead Sciences ,- ViiV Healthcare ,- Merck & Co ,- Janssen ,- Bristol-Myers Squibb ,- AbbVie |
MARKET FORECAST PERIOD | 2024 - 2032 |
KEY MARKET OPPORTUNITIES | 1 Increasing prevalence of HIV 2 Development of new and effective drugs 3 Growing demand for generic drugs 4 Expansion of access to treatment 5 Rise in government funding |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.49% (2024 - 2032) |
The Philippines reported about ****** HIV cases, an increase from the previous year. The number of reported HIV cases has gradually increased since 2012, aside from a significant dip in 2020. The state of HIV As the monthly average number of people newly diagnosed with HIV increases, the risk it poses threatens the lives of Filipinos. HIV is a sexually transmitted infection that attacks the body’s immune system, with more males being diagnosed than females. In 2022, the majority of people newly diagnosed with HIV were those between the age of 25 and 34 years, followed by those aged 15 and 24. There is still no cure for HIV and without treatment, it could lead to other severe illnesses such as tuberculosis and cancers such as lymphoma and Kaposi’s sarcoma. However, HIV is now a manageable chronic illness that can be treated with proper medication. What are the leading causes of death in the Philippines? Between January and September 2024, preliminary figures have shown that ischaemic heart disease was the leading cause of death in the Philippines. The prevalence of heart diseases in the nation has been closely attributed to the Filipino diet, which was described as having a high fat, high cholesterol, and high sodium content. In addition, acute respiratory infections and hypertension also registered the highest morbidity rate among leading diseases in the country in 2021.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 7.08(USD Billion) |
MARKET SIZE 2024 | 7.54(USD Billion) |
MARKET SIZE 2032 | 12.5(USD Billion) |
SEGMENTS COVERED | Route of Administration ,Application ,Dosage Strength ,Combination Therapies ,Distribution Channel ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Increasing prevalence of chronic diseases Rising geriatric population Technological advancements Growing awareness of lopinavir Increasing research and development activities |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | GlaxoSmithKline ,Sanofi ,Bristol Myers Squibb ,Pfizer ,Johnson & Johnson ,AbbVie ,Novartis ,Amgen ,Merck & Co ,Eli Lilly and Company ,Biogen ,Baxter International ,Gilead Sciences ,Roche ,Takeda Pharmaceutical Company |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Growing Prevalence of HIVAIDS Rising Demand in Developing Countries Technological Advancements Expanding Biosimilar Market Government Initiatives |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.52% (2025 - 2032) |
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Finland was reported at 0.1 % in 2018, according to the World Bank collection of development indicators, compiled from officially recognized sources. Finland - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, male (% ages 15-24) in Ghana was reported at 0.3 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Ghana - Prevalence of HIV, male (% ages 15-24) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.